The PREPARE study: benefits of pharmacogenetic testing are unclear

Affiliations

Comment

David Curtis. Lancet. 2023.

. 2023 Jun 3;401(10391):1850-1851.

doi: 10.1016/S0140-6736(23)00854-1.

¹ UCL Genetics Institute, UCL, London WC1E 6BT, UK. Electronic address: d.curtis@ucl.ac.uk.

No abstract available

Comment in

The PREPARE study: benefits of pharmacogenetic testing are unclear - Authors' reply.
Swen JJ, Manson LEN, Böhringer S, Pirmohamed M, Guchelaar HJ. Swen JJ, et al. Lancet. 2023 Jun 3;401(10391):1851-1852. doi: 10.1016/S0140-6736(23)00852-8. Lancet. 2023. PMID: 37270238 No abstract available.

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.